NASH: A glance at the landscape of pharmacological treatment
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 5
Abstract
The role of nonalcoholic fatty liver disease, namely nonalcoholic steatohepatitis (NASH), as risk factor for liver- and non-liver-related morbidity and mortality has been extensively reported. In addition to lifestyle changes, capable of removing the metabolic factors driving disease progression, there is an urgent need for drugs able to reduce hepatic necroinflammation without worsening of fibrosis. This goal is considered by regulatory agencies as surrogate marker to define the effectiveness in pharmacological compounds in NASH, and fast-track approval was granted by the Food and Drug Administration in consideration of disease severity and unmet medical needs. Several compounds are in the pipeline of pharmaceutical industries and are being studied in phase II trials, but only a few (obeticholic acid, elafibranor) have started phase III trials. This concise review is intended to offer a systematic analysis of the most promising therapeutic intervention in NASH. In conclusion, there is reasonable expectation that drug may help curb the burden of NASH, and we look forward to obtaining solid data on their long-term safety and effectiveness. However, we should not forget that behavioral interventions remain a mandatory background treatment, able to stop disease progression in compliant overweight/ obese patients, with results that compare favorably with - and add to - the beneficial effects of drug treatment.
Authors and Affiliations
Lucia Brodosi, Francesca Marchignoli, Maria Petroni, Giulio Marchesini
Keywords
Related Articles
- EP ID EP78611
- DOI 10.5604/16652681.1212318
- Views 109
- Downloads 0
Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B
Background. Long-term lamivudine (LAM), adefovir (ADV) and entecavir (ETV) treatment induce the emergence of drug-resistant hepatitis B virus (HBV) in patients with chronic hepatitis B infection. Aim. To evaluate the LAM...
Percutaneous shunt reduction for the management of TIPS-induced acute liver decompensation: A follow-up study
Background and rationale for the study. The purpose of this study was to assess the technical and clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) reduction for the management of TIPS-induced ac...
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
Background. Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia...
Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal stat
Introduction. Liver disease is a major health issue in Mexico. Although several studies have been performed to analyze the impact of liver diseases on the Mexican population, none has compared the prevalence and impact o...
Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico
Background. The evolving pattern of HCV genotypes (GTs) and risk factors (RFs) in HCV-infected patients in Mexico is poorly understood. This study aimed to access the temporal trend of HCV GTs and RFs in HCV patients fro...